Bio-Statistician Knut M. Wittkowski Will Not Be Silenced

Censored on social media platform Youtube, he continues to speak.

Read him here

Bio:
Dr. Wittkowski received his PhD in computer science from the University of Stuttgart and his ScD (Habilitation) in Medical Biometry from the Eberhard-Karls-University Tuüingen, both Germany. He worked for 15 years with Klaus Dietz, a leading epidemiologist who coined the term “reproduction number”, on the Epidemiology of HIV before heading for 20 years the Department of Biostatistics, Epidemiology, and Research Design at The Rockefeller University, New York. Dr. Wittkowski is currently the CEO of ASDERA LLC, a company discovering novel treatments for complex diseases from data of genome-wide association studies.

Let Logic Guide Us

https://youtu.be/rhEQlkR3-Ow

Who should be tested?

Neurologist Scott Atlas suggests the following groups should currently be tested:

  • Anyone who accesses nursing homes
  • Anyone who contacts the vulnerable (first responders, hospital/medical workers, etc)
  • Patients with respiratory symptoms

He explains that with the insufficient knowledge available early-on the initial general lockdown was reasonable. He suggests that with current data the extension of lockdown is unnecessary and that we should take a careful, well planned layer by layer exit.

Major League Baseball Antibody Test Results

“After adjusting to reflect testing accuracy, that comes to a positive test rate of 0.7 percent. As Passan notes that’s a lower figure than other notable antibody test studies have yielded. Furthermore, 70 percent of those who tested positive were asymptomatic — i.e., they presented no symptoms of having COVID-19. The tests were conducted in the middle of April.”

https://www.cbssports.com/mlb/news/mlb-coronavirus-antibody-study-results-less-than-one-percent-of-participants-test-positive/

Identifying Antibody – Appears 100% Effective, STI-1499

https://www.biospace.com/article/sorrento-ids-antibody-against-covid-19-that-appears-100-percent-effective/

“We’re actually so impressed with the data,” Li said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.”

That was STI-1499.

[…]

“We anticipate having enough material to start a Phase I trial in patients in the ICU within two months. If that is successful, we will expand that trial using our cGMP facility which can produce 2,000 liters of material, which is enough for approximately 100,000 patients, based on what we think the dose will be,” Brunswick said.

The antibody is potentially both a preventative and a treatment. It prevents the virus from binding to the cell it wants to bind to, which means it can’t enter the cell and reproduce.

(Read details at above link)